Lucis Pharma
Lucis Pharma is a UK-based private pharmaceutical company founded in 2012 that develops and licenses high-quality generic medicines for healthcare professionals and patients. It was acquired by Rosemont Pharmaceuticals in June 2023.
- Company typePrivate
- Founded2012
- HeadquartersBlockley, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lucis Pharma does
Lucis Pharma is a privately held UK pharmaceutical company founded in 2012 and headquartered in Blockley, United Kingdom, specializing in the development and licensing of high-quality generic medicines. The company targets the healthcare professional segment — doctors, pharmacists, and other prescribers — alongside end patients seeking affordable medication options, with the stated mission of improving healthcare accessibility and affordability through generic formulations that meet rigorous safety and efficacy standards.
Lucis's core offering is a portfolio of generic medicines marketed through pharmacy and healthcare professional channels, supplemented by pipeline products targeting the unit dose/sachet market segment. The company executed product launches during the 2021/22 period, though specific product names and therapeutic indications are not disclosed in available source material. The underlying business model centers on licensing generic pharmaceutical products, with revenue mechanics structured around one-time licensing arrangements rather than recurring subscription or service fees.
In June 2023, Lucis Pharma was acquired by Rosemont Pharmaceuticals, a larger UK-based specialty pharmaceutical group. Following the acquisition, Lucis operates as a subsidiary within the Rosemont group, with the deal positioned by Rosemont as a vehicle for portfolio broadening, entry into attractive new product areas, and access to Lucis's pipeline including unit dose/sachet formulations. No disclosed financial metrics, headcount, or management team details are available in the source data.
Lucis Pharma firmographics
Firmographics- Name
- Lucis Pharma
- Legal name
- Lucis Pharma Ltd
- Website
- https://lucispharma.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Short description
- Lucis Pharma is a UK-based private pharmaceutical company founded in 2012 that develops and licenses high-quality generic medicines for healthcare professionals and patients. It was acquired by Rosemont Pharmaceuticals in June 2023.
- Ownership category
- akta.pro rank
Lucis Pharma industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Generic Hospital & Institutional Products (HLAIABAL)
- akta.pro secondary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Lucis Pharma is headquartered
LocationHeadquarters
- HQ city
- Blockley
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Lucis Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Revenue model
- Generic Pharmaceutical Products: Revenue generated through development and licensing of high-quality generic medicines. Products are marketed to improve healthcare accessibility and affordability.
Go-to-market motion1 record
Lucis Pharma product offering
Product offeringCore offering
Lucis Pharma develops and licenses high-quality generic medicines focused on improving healthcare accessibility and affordability. The portfolio includes recently launched products from 2021/22 and pipeline products enabling entry into the unit dose/sachet market. Products are marketed to healthcare professionals including doctors, pharmacists, and other prescribers for use in patient care.
Product overview
Lucis Pharma operates as a specialist pharmaceutical company focused on the development and licensing of high-quality generic medicines. Founded in 2012, the company is committed to improving healthcare accessibility and affordability by delivering effective and safe medications that meet rigorous standards. Following its acquisition by Rosemont Pharmaceuticals in June 2023, Lucis Pharma's portfolio provides access to new product areas and pipeline products, including unit dose/sachet formulations.
Differentiator
Problem solved
Functional benefit
Products and services
- Generic Medicines Portfolio
Companies that use Lucis Pharma
Customer profileSegments2 records
Ideal customer profiles1 record
Lucis Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lucis Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Rosemont PharmaceuticalscoreRosemont Pharmaceuticals acquired Lucis Pharma Ltd in June 2023. The acquisition brings accelerated growth opportunities through broadened portfolio, access to new attractive product areas, and further pipeline products including unit dose/sachet market entry.
Scale indicators1 record
Recent moves3 records
Expansion highlights2 records
Lucis Pharma competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses4 records
Competitive moat1 record
Key risks4 records
Customer concentration
Lucis Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lucis Pharma leadership team
Management profileNumber of profiles
Lucis Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lucis Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lucis Pharma
What does Lucis Pharma do?
Lucis Pharma develops and licenses high-quality generic medicines focused on improving healthcare accessibility and affordability. The portfolio includes recently launched products from 2021/22 and pipeline products enabling entry into the unit dose/sachet market. Products are marketed to healthcare professionals including doctors, pharmacists, and other prescribers for use in patient care.
Is Lucis Pharma a public or private company?
Lucis Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was Lucis Pharma founded?
Lucis Pharma was founded in 2012.
Where is Lucis Pharma based?
Lucis Pharma is headquartered in Blockley, United Kingdom, in the Europe region.
How does Lucis Pharma make money?
One revenue line is on record: generic Pharmaceutical Products.
Does Lucis Pharma have an API?
No public API is recorded for Lucis Pharma.
What industry is Lucis Pharma in?
Lucis Pharma's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAL, Generic Hospital & Institutional Products, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.